Psilocybin: from ancient magic to modern medicine

Secondary metabolites from plants, fungi and bacteria have long been a source of therapeutic agents, especially for anti-infective and anticancer drugs. Treatments for central nervous system disorders have been less commonly derived from such metabolites. Nichols frames psilocybin, a fungal secondary metabolite produced by more than 200 species of basidiomycetes, as an emerging candidate for treating a range of psychiatric conditions including depression, anxiety and certain addictions. This short review aims to trace psilocybin from its ethnographic and chemical discovery through modern advances in synthesis, biosynthetic engineering, neurobiology and clinical studies. The paper synthesises historical background, analytical and synthetic chemistry, enzymology and recent human research to assess the current state of evidence and the prospects for clinical translation.

The extracted text does not report a formal, reproducible search strategy or systematic-review methods; the paper is presented as a narrative review that integrates diverse evidence streams. Nichols summarises historical records, chemical isolation and synthesis routes, enzymatic biosynthesis studies, preclinical pharmacology, human neuroimaging and results from clinical trials and pilot studies. Evidence types included in the review comprise ethnographic and historical accounts, chemical characterisation and synthetic-method development, genomic and enzymatic studies that reconstitute biosynthetic pathways, biotechnological production efforts in recombinant organisms, animal pharmacology that informed mechanism, human imaging studies (PET, ASL, BOLD fMRI, MEG), and clinical research ranging from open-label pilot studies to randomised, double-blind, placebo- or active-controlled crossover trials. Where available, the review reports sample sizes, doses, clinical endpoints and follow-up durations from these primary studies, but it does not provide a formal risk-of-bias assessment or meta-analytic pooling of effect sizes.

History and chemical identification: Nichols recounts early ethnographic documentation of the sacred “teonanacatl” mushrooms in Mesoamerica, their rediscovery in the 20th century and the isolation and total synthesis of psilocybin by Albert Hofmann. Psilocybin (4‑phosphoryloxy‑N,N‑dimethyltryptamine) is a stable, water‑soluble crystalline compound; its dephosphorylated derivative, psilocin, is less stable and not water soluble. Dose, pharmacology and molecular target: Analysis of multiple mushroom species shows psilocybin plus psilocin content ranging roughly from 0.1% to nearly 2% dry weight in species used recreationally. A medium oral dose is reported as 4–8 mg of psilocybin, producing effects that typically last 2–6 hours. Psilocybin is rapidly dephosphorylated in vivo to psilocin, which is the pharmacologically active species; psilocin acts as an agonist at cortical serotonin 5‑HT2A receptors, a mechanism now generally accepted to mediate psychedelic effects. Chemical synthesis and biotechnological production: Hofmann’s original chemical synthesis was improved over time. Kargbo et al. developed a phosphorylation route using phosphorus oxychloride that eliminated hazardous reagents and was used to produce 1.21 kg of cGMP material. Genomic and enzymatic work by Fricke and colleagues identified four biosynthetic enzymes (PsiD, PsiH, PsiK, PsiM) and reconstituted an enzymatic route from 4‑hydroxy‑L‑tryptophan; a hybrid chemical/biocatalytic approach converted psilocin to psilocybin via PsiK, yielding 1 g of psilocybin from psilocin within 20 minutes. Adams et al. reported a modular biosynthetic platform in Escherichia coli with optimisation yielding a 32‑fold titer improvement and a fed‑batch production titer of 1.16 g/L, representing the highest reported recombinant‑organism psilocybin titre to date. Clinical studies and therapeutic signals: Nichols summarises a range of human studies, from small open‑label reports to larger randomised, double‑blind trials. Early uncontrolled work produced limited therapeutic evidence through the 1960s–1980s. More recently, multiple controlled and uncontrolled clinical studies have reported clinically meaningful effects: - Moreno et al.: an open‑label study in nine subjects with obsessive‑compulsive disorder reported acute reductions in core OCD symptoms and acceptable safety. - Grob et al.: a placebo‑controlled study in 12 adults with advanced cancer and anxiety administered 0.2 mg/kg psilocybin and reported significant reductions in trait anxiety at 1 and 3 months and improvement in Beck Depression Inventory scores reaching significance at 6 months; no clinically significant adverse events were noted. - Johnson et al.: an open‑label pilot smoking‑cessation protocol with either 20 mg/70 kg or 30 mg/70 kg doses in 15 nicotine‑dependent smokers produced 7‑day point‑prevalence abstinence in 12/15 participants (80%) at 6 months. - Bogenschutz et al.: a small placebo‑controlled study of psilocybin‑assisted psychotherapy for alcohol dependence (n = 10) found abstinence increased significantly after psilocybin administration with gains largely maintained at 36‑week follow‑up; session intensity predicted later reductions in drinking and craving. - Griffiths et al.: a randomised, double‑blind, crossover trial in 51 cancer patients compared a very low (1 or 3 mg/70 kg) to a high (22 or 30 mg/70 kg) dose; the high dose produced large, significant decreases in clinician‑ and self‑rated depressed mood and anxiety, increased measures of quality of life, meaning and optimism, and reductions in death anxiety. Approximately 80% of participants continued to show clinically significant decreases in mood/anxiety at 6 months. - Ross et al.: a double‑blind, placebo‑controlled crossover trial in 29 patients with cancer‑related anxiety/depression randomised to a single 0.3 mg/kg psilocybin dose versus niacin (with psychotherapy) found rapid and robust anxiolytic and antidepressant effects prior to crossover; at 6.5 months ~60–80% of participants continued to show clinically significant reductions in depression or anxiety. Across these clinical reports, mystical‑type acute experiences during dosing sessions were reported to mediate longer‑term therapeutic benefits in several studies. The FDA has granted Breakthrough Therapy designation to psilocybin for treatment‑resistant depression and for major depressive disorder in specific sponsored trials. Neuroimaging and neural mechanisms: Multiple imaging modalities converge on 5‑HT2A receptor‑mediated alterations in cortical activity and network organisation. Early PET studies reported global increases in cerebral glucose metabolism with pronounced frontal increases that correlated with subjective “ego dissolution.” Other studies using ASL and BOLD fMRI reported decreases in cerebral blood flow and BOLD signal in hub regions (thalamus, anterior and posterior cingulate, mPFC), with reduced coupling between mPFC and PCC and decreased default‑mode network (DMN) integrity. Subsequent perfusion studies showed both relative increases and decreases in specific regions depending on whether global perfusion was adjusted for, emphasising analysis sensitivity. MEG studies demonstrated reductions in spontaneous oscillatory power across wide frequency bands, particularly in posterior association cortices and DMN regions; dynamic causal modelling implicated increased excitability of deep‑layer pyramidal neurons rich in 5‑HT2A receptors. Animal and cellular work supports direct activation of a subset of deep cortical pyramidal cells and subsequent recruitment of interneurons and glia, providing a mechanistic basis for network desynchronisation and the altered repertoire of brain connectivity seen after psilocybin. Longer‑term neural and affective changes: Some studies report enduring changes after single administrations, including reduced negative affect and amygdala responses to affective stimuli at one week, sustained increases in positive affect and reduced trait anxiety at one month, and an increased number of significant resting‑state functional connections from baseline to one week and one month post‑psilocybin.

Nichols interprets the assembled evidence as indicating that psilocybin has substantive potential as a therapeutic adjunct in psychiatry, particularly for end‑of‑life distress, depression, anxiety and certain addictions. He places modern clinical findings within a longer historical and chemical narrative, arguing that recent rigorous trials mark a renaissance in psychedelic research after decades of limited controlled work. The review emphasises a mechanistic consistency across levels of analysis: psilocybin is a prodrug for psilocin, which activates cortical 5‑HT2A receptors, leading to desynchronisation of canonical network activity, transient disruption of default‑mode and hub connectivity and emergence of novel large‑scale functional connections; these acute neural effects correlate with subjective mystical‑type experiences that appear to mediate lasting therapeutic changes in mood, outlook and behaviour in several studies. Limitations and uncertainties acknowledged by the paper include the small sample sizes and the heterogeneity of study designs in many of the cited clinical trials, the mixture of open‑label and controlled designs, and sensitivity of imaging findings to analytic methods. Nichols notes that several clinical trials are ongoing and that larger, well‑controlled studies are required to validate early positive findings before psilocybin can be confidently integrated into routine psychiatric practice. Practical implications highlighted by the authors include advances in scalable synthesis and biosynthetic production that could support clinical development and commercial manufacture, and regulatory momentum exemplified by FDA Breakthrough Therapy designations. Nichols frames these developments as enabling further translational research while underscoring the need for validation in larger samples.

Over the past 10–15 years, several modern clinical studies have provided preliminary evidence that psilocybin‑assisted psychotherapy can produce rapid, durable reductions in anxiety, depression and some addictive behaviours. Given recent advances in chemical and biotechnological production and growing mechanistic understanding, psilocybin is presented as poised to have a substantial impact on psychiatric treatment if the promising early results are confirmed by larger trials and regulatory processes proceed.